Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branford

Showing results (381-390 of 480) with videos related to

Pageof 48
Sort By:
Leukemia|October 3, 2003
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseS Branford, Z Rudzki, A Harper, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Leukemia|May 17, 2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRC H Hui, K Y Goh, D White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Nature Communications|May 14, 2024
Ultrastrong magnon-magnon coupling and chiral spin-texture control in a dipolar 3D multilayered artificial spin-vortex iceTroy Dion, Kilian D Stenning, Alex Vanstone, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Pageof 48

Showing results (381-390 of 480) with videos related to

Sort By:
Pageof 48
Leukemia|October 3, 2003
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseS Branford, Z Rudzki, A Harper, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Leukemia|May 17, 2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRC H Hui, K Y Goh, D White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Nature Communications|May 14, 2024
Ultrastrong magnon-magnon coupling and chiral spin-texture control in a dipolar 3D multilayered artificial spin-vortex iceTroy Dion, Kilian D Stenning, Alex Vanstone, et al.
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Pageof 48